MannKind to Present at 2024 UBS Healthcare Conference
MannKind (Nasdaq: MNKD) has announced its participation in the 2024 UBS Healthcare Conference in Rancho Palos Verdes, California. CEO Michael Castagna and CFO Chris Prentiss will participate in a fireside chat on Tuesday, November 12, at 10:15 a.m. Pacific Time. The company, which specializes in developing inhaled therapeutic products for endocrine and orphan lung diseases, will provide company updates during the session. The presentation will be accessible via live audio webcast on MannKind's website, with a recorded version available for approximately 30 days after the event.
MannKind (Nasdaq: MNKD) ha annunciato la sua partecipazione alla Conferenza Sanitaria UBS 2024 che si terrà a Rancho Palos Verdes, California. Il CEO Michael Castagna e il CFO Chris Prentiss parteciperanno a una chiacchierata al caminetto martedì 12 novembre, alle 10:15 ora del Pacifico. L'azienda, che si specializza nello sviluppo di prodotti terapeutici inalabili per malattie endocrine e polmonari rare, fornirà aggiornamenti aziendali durante la sessione. La presentazione sarà accessibile tramite diretta audio sul sito web di MannKind, con una versione registrata disponibile per circa 30 giorni dopo l'evento.
MannKind (Nasdaq: MNKD) ha anunciado su participación en la Conferencia de Salud UBS 2024 en Rancho Palos Verdes, California. El CEO Michael Castagna y el CFO Chris Prentiss participarán en una charla junto al fuego el martes 12 de noviembre a las 10:15 a.m. hora del Pacífico. La empresa, que se especializa en el desarrollo de productos terapéuticos inhalados para enfermedades endocrinas y pulmonares raras, proporcionará actualizaciones de la empresa durante la sesión. La presentación estará disponible a través de una transmisión de audio en vivo en el sitio web de MannKind, con una versión grabada disponible durante aproximadamente 30 días después del evento.
MannKind (Nasdaq: MNKD)는 캘리포니아 랜초 팔로스 베르데스에서 열리는 2024 UBS 의료 회의에 참가한다고 발표했습니다. CEO 마이클 카스타냐와 CFO 크리스 프렌티스는 태평양 표준시로 11월 12일 화요일 오전 10:15에 화상 대화에 참여할 예정입니다. 내분비 및 희귀 폐 질환용 흡입형 치료 제품 개발을 전문으로 하는 이 회사는 세션 중 회사 업데이트를 제공할 것입니다. 발표는 MannKind 웹사이트에서 라이브 오디오 웨비나로 이용 가능하며, 이벤트 후 약 30일 동안 녹음된 버전도 제공될 예정입니다.
MannKind (Nasdaq: MNKD) a annoncé sa participation à la Conférence Santé UBS 2024 à Rancho Palos Verdes, Californie. Le PDG Michael Castagna et le directeur financier Chris Prentiss participeront à une discussion informelle le mardi 12 novembre à 10h15, heure du Pacifique. L'entreprise, qui se spécialise dans le développement de produits thérapeutiques inhalés pour les maladies endocriniennes et pulmonaires rares, fournira des mises à jour sur l'entreprise lors de la session. La présentation sera accessible via une diffusion audio en direct sur le site web de MannKind, avec une version enregistrée disponible pendant environ 30 jours après l'événement.
MannKind (Nasdaq: MNKD) hat seine Teilnahme an der 2024 UBS Gesundheitskonferenz in Rancho Palos Verdes, Kalifornien, bekannt gegeben. CEO Michael Castagna und CFO Chris Prentiss werden am Dienstag, den 12. November, um 10:15 Uhr Pacific Time an einem Kaminabend teilnehmen. Das Unternehmen, das sich auf die Entwicklung von inhalativen Therapeutika für endokrine und orphan Lungenerkrankungen spezialisiert hat, wird während der Sitzung Unternehmensaktualisierungen bereitstellen. Die Präsentation wird über einen Live-Audiowebcast auf der Website von MannKind zugänglich sein, während eine aufgezeichnete Version etwa 30 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during a fireside chat at the 2024 UBS Healthcare Conference in Rancho Palos Verdes, Calif.
The fireside chat will take place on Tuesday, November 12, at 10:15 a.m. Pacific Time. A link to the live audio webcast of the session will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available on the website for approximately 30 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
This press release was published by a CLEAR® Verified individual.
FAQ
When is MannKind (MNKD) presenting at the 2024 UBS Healthcare Conference?
How can I watch MannKind's (MNKD) presentation at the UBS Healthcare Conference?
How long will MannKind's (MNKD) UBS Conference presentation recording be available?
Which MannKind (MNKD) executives are presenting at the 2024 UBS Healthcare Conference?
